Dementia Focus: Exploring the utility of the Multi-Dementia Laboratory test in clinical practice and clinical trial settings
We aim to evaluate the Multi-Dementia Laboratory test’s effectiveness in accurately identifying different dementia types
Amsterdam UMC – Neurochemistry Lab and Olink Proteomics have partnered to evaluate the Multi-Dementia Panel, a novel cerebrospinal fluid (CSF)-based diagnostic tool that measures 42 proteins simultaneously. This innovation aims to improve the diagnosis of different neurodegenerative dementias including: Alzheimer’s disease (AD), Dementia with Lewy Bodies (DLB), and Frontotemporal Dementia (FTD). Through collaboration with Eisai, the project takes a significant step forward by exploring its potential use in clinical trials to enhance patient selection and treatment effect monitoring.
Dementia affects over 55 million people worldwide, with diagnoses often delayed or inaccurate due to overlapping symptoms. This uncertainty contributes to misdiagnosis, ineffective treatments, and a growing burden on healthcare systems. Early and precise diagnosis is crucial for timely intervention, improved patient care, and more efficient clinical trials. The Multi-Dementia Panel offers a promising solution by reducing diagnostic uncertainty, enabling targeted treatments, and potentially lowering healthcare costs by decreasing reliance on expensive imaging techniques like PET scans.
By leveraging advanced biomarker analysis in CSF, this project introduces an accurate and cost-effective alternative to current diagnostic methods. The Multi-Dementia Panel will be evaluated in clinical settings and clinical trials, with cross-sectional and longitudinal analyses to assess its ability to differentiate between dementia subtypes and track disease progression over time. If successful, the panel could advance dementia diagnostics, improving patient care and optimizing clinical trial outcomes.
This project will generate comprehensive biomarker data across diverse patient cohorts and clinical trial samples, strengthening the evidence base for its clinical utility. The findings will provide valuable insights into dementia pathophysiology and could support broader applications of the panel in clinical practice.
Andere projecten
In elk PPS-project werken kennisinstellingen, bedrijven en zorgpartijen samen aan een concrete gezondheidsvraag. Bekijk het volledige projectoverzicht.
Bekijk de programma’s
Binnen onze programma’s werken bedrijven, kennisinstellingen en regionale partners samen aan innovaties die bijdragen aan betere gezondheid en zorg.
Bekijk de partnerschappen
Strategische publiek-private partnerschappen (PPP's) zijn meerjarige samenwerkingen tussen bedrijven, kennisinstellingen en andere partijen.
Hoe kunnen we je helpen?
Heb je een vraag of wil je meer weten over Health Holland? We brengen je graag in contact met de juiste mensen, kennis en mogelijkheden om gezondheidsinnovatie te versnellen.
We hebben uw bericht ontvangen
We nemen binnen 3 tot 4 werkdagen contact met je op. Is je vraag dringend? Neem dan gerust direct contact met ons op. Hieronder zie je de contactoptie die het beste past bij je onderwerp.
Opnieuw beginnen
Er ging iets mis bij het versturen van het formulier. Probeer het opnieuw.